Takeda stops supplies of three key drugs to Russia

Japanese pharma giant Takeda (TYO: 4502) has officially announced the suspension of supplies of at least three branded generic drugs to the Russian market this year, reports The Pharma Letter’s local correspondent.

Among these drugs are Atenolol Nycomed, which is designed for the treatment of arrhythmia, Amitriptyline Nycomed (an antidepressant) and an antiprotozoal drug Metronidazole Nycomed. All of these are in the list of vital and essential drugs in Russia, pricing for which is regulated by the state.

In the case of Atenolol Nycomed, at present it accounts for almost 60% of sales in its segment, with its withdrawal from the market likely resulting in a shortage of drugs against arrhythmia in Russia in the coming weeks.